News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CardioMetabolics Announces it has all Approvals in Place to Commence its Phase II Mini-METRxICS Trial



7/12/2007 11:42:03 AM

EDMONTON, July 12 /CNW/ - CardioMetabolics Inc., a Canadian biopharmaceutical company, announced today that all approvals have been received authorizing the start of their Phase II "Mini-METRxICS" Clinical Trial, which is aimed at reducing Intensive Care Unit (ICU) stays in geriatric patients undergoing cardiopulmonary bypass surgery. Dr. Ruth Collins-Nakai, CMI's Chief Medical Officer commented that, "we are excited to start this trial of a drug that has the potential to help such a large number of patients globally. According to the American Heart Association, in the US alone, each year more than 750,000 patients undergo open heart surgical procedures!"

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES